Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PTPRB | P23467 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL23303501 | 1.00 | MAPT (0.40) | MAPTMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL501297 | 0.99 | MAPT (0.41) | MAPTMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL683502 | 0.99 | MAPT (0.41) | MAPTMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL17083263 | 0.99 | MAPT (0.41) | MAPTMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL16573552 | 0.85 | MEN1 (0.43) | MAPTMEN1KMT2ATDP1L3MBTL1 | |
| Bromide SCHEMBL27753219 | 0.85 | MAPT (0.47) | MAPTMEN1KMT2ATDP1L3MBTL1 | |
| Bromide SCHEMBL500372 | 0.85 | MAPT (0.47) | MAPTMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL684367 | 0.84 | MAPT (0.48) | MAPTMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL8769233 | 0.84 | MAPT (0.48) | MAPTMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL8587434 | 0.83 | PTPRB (0.46) | MAPTMEN1KMT2ATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187715-B2 | Small molecule activators of Tie-2 | EyePoint Pharmaceuticals, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| US-12152023-B2 | Compositions, formulations and methods for treating ocular diseases | EyePoint Pharmaceuticals, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| CN-117460743-A | Small molecule VE-PTP inhibitors | 曼宁研究公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20230265087-A1 | SMALL MOLECULE ACTIVATORS OF TIE-2 | EyePoint, Inc. | 2023-08-24 | — | — | US | disclosed |
| EP-4164690-A1 | SMALL MOLECULE VE-PTP INHIBITORS | Ripka, Amy (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11613534-B2 | Small molecule activators of Tie-2 | EyePoint Pharmaceuticals, Inc. (US) | 2023-03-28 | — | — | US | disclosed |
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-4051267-A1 | SMALL MOLECULE ACTIVATORS OF TIE-2 | EyePoint Pharmaceuticals, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220274976-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint, Inc. | 2022-09-01 | — | — | US | disclosed |
| CN-114939117-A | Method of treating vascular leak syndrome | 视点制药公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20120128625-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EyePoint, Inc. | 2012-05-24 | — | — | US | disclosed |
| US-20120129847-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2012-05-24 | — | — | US | disclosed |
| US-20120077975-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHOD OF USE | EyePoint Pharmaceuticals, Inc. | 2012-03-29 | — | — | US | disclosed |
| US-8106078-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | WARNER CHILCOTT COMPANY, LLC (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2011-11-03 | — | — | US | disclosed |
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2011-09-01 | — | — | US | disclosed |
| US-7795444-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Warner Chilcott Company (US) | 2010-09-14 | — | — | US | disclosed |
| EP-2038265-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008002570-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129847-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | SLC6A3 3974/4885MAPT 1793/4885MEN1 4832/4885 |
| US-20120128625-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EPCAM, CD44, CDH1 | SLC6A3 2328/4885MAPT 4288/4885MEN1 969/4885 |
| US-20120077975-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHOD OF USE | PTPRCAP, PPP5C, PTPRO | SLC6A3 3418/4885MAPT 3034/4885MEN1 3862/4885 |
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | SLC6A3 3585/4885MAPT 3021/4885MEN1 3881/4885 |
| US-11613534-B2 | Small molecule activators of Tie-2 | TIE1, TEK, KDR | SLC6A3 4694/4885MAPT 2343/4885MEN1 1276/4885 |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | SLC6A3 611/4885MAPT 4517/4885MEN1 999/4885 |
| US-20230265087-A1 | SMALL MOLECULE ACTIVATORS OF TIE-2 | TIE1, TEK, KDR | SLC6A3 4694/4885MAPT 2343/4885MEN1 1276/4885 |
| US-20220274976-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | SLC6A3 4219/4885MAPT 650/4885MEN1 875/4885 |
| US-12152023-B2 | Compositions, formulations and methods for treating ocular diseases | TIE1, TEK, KDR | SLC6A3 4219/4885MAPT 650/4885MEN1 875/4885 |
| US-12187715-B2 | Small molecule activators of Tie-2 | TIE1, TEK, KDR | SLC6A3 4694/4885MAPT 2343/4885MEN1 1276/4885 |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | PTPRCAP, PTPRC, PPP5C | SLC6A3 3585/4885MAPT 3021/4885MEN1 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.